[ivory-search id="184" title="Recordati AJAX Search Form"]

Investor
Relations

Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.

Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.

Investor
Relations

Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.

Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.


Upcoming Events

No upcoming events found.

Date:

June 25, 2024

Stifel European Healthcare Summit

Location:

Lyon

Date:

July 30, 2024

Board of Directors’ meeting to approve the 2024 half-yearly report.

Date:

November 8, 2024

Board of Directors’ meeting to approve the 2024 first nine months’ results, as additional voluntary financial reporting.

Revenue trend 2019 - 2023 (million Euro)

No Data Found

Revenue by business unit 2019 - 2023 (million Euro)​

No Data Found

Total Revenue split by Therapeutica area - FY 2023
(SPC 63.1%, Rare Disease 34.3%) ​

No Data Found

Note: Total OTC of € 331.3 million in FY 2023 and € 300.7 million in FY 2022 Subsidiaries’ local product portfolios of € 238.4 million in FY 2023 and € 237.1 million in FY 2022

Pharmaceutical revenue (excluding Chemicals) split by Geographic - FY 2023

No Data Found

Key P&L Data

(million Euro)
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
Revenue
2,082.3
1,853.3
1,580.1
1,448.9
1,481.8
Gross Profit
as % of revenue
1,422.6
68.3
1,286.6
69.4
1,152.3
72.9
1,042.0
71.9
1,044.9
70.5
Adjusted Gross Profit (1)
as % of revenue
1,481.6
71.1
1,336.4
72.1
1,152.3
72.9
1,042.0
71.9
1,044.9
70.5
Operating Income (EBIT)
as % of revenue
558.0
26.8
437.3
23.6
490.2
31.0
469.0
32.4
465.3
31.4
Adjusted Operating Income (Adj. EBIT) (2)
as % of revenue
626.6
30.1
536.1
28.9
504.6
31.9
469.0
32.4
465.3
31.4
Net Income
as % of revenue
389.2
18.7
312.3
16.9
386.0
24.4
355.0
24.5
368.9
24.9
Adjusted Net Income (3)
as % of revenue
524.6
25.2
473.3
25.5
424.6
26.9
410.4
28.3
382.4
25.8
EBITDA (4)
as % of revenue
769.6
37.0
672.8
36.3
602.3
38.1
569.3
39.3
544.0
36.7
1) Gross profit adjusted from impact of non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS 3)

2) Net income before income taxes, financial income and expenses, non-recurring items, and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS 3)

3) Net income excluding amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS 3) and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects

4) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS 3)

Balance Sheet at December 2023 (million Euro)

No Data Found

No Data Found

No Data Found

Net Debt - FY 2021 - 2023 (million Euro)
Net Debt / EBITDA1 - FY 2021 - 2023 (million Euro)

No Data Found

1) Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma to the gross margin of acquired inventory (IFRS). 

*EBITDA pro-forma considering the contribution of Avodart® and Combodart®/Duodart® for the last twelve months (as was stated in the press release / presentation)

Free Cash Flow1 - FY 2021 - 2023 (million Euro)

No Data Found

1) Operating cash flow excluding financing items, milestones, dividends, purchases of treasury shares net of proceeds from exercise of stock options
Shareholders' Equity Per Share (Euro)​

No Data Found

Adjusted Net Income Per Share (Euro)

No Data Found

Dividend per share (Euro)

No Data Found

Net Income per share (Euro)

No Data Found

Presentations & Reports

Latest and previous presentations and reports including company presentations and financial results, annual & interim reports and archived materials…

Press Releases

Overview of our key milestones as a company and latest news and announcements


Share Price

Contacts
Engagement Policy

In Partenza Recordati.com

Stai per lasciare recordati.com per accedere al sito dedicato alle carriere di Recordati

Leaving Recordati.com

You are now leaving recordati.com to enter Recordati’s dedicated career site

INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003

The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.

 

In any event we assure you that your data will be processed solely for the above purposes and using the above methods.

 

The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.

 

A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).

 

Requests must be sent to the Data Processor of Recordati:
   by email, to the address: ;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.

 

In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.

 

Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.